Stevens–Johnson syndrome-like cutaneous toxicity with enfortumab vedotin in treating metastatic urothelial carcinoma: A case report

Stevens–Johnson syndrome-like cutaneous toxicity with enfortumab vedotin in treating metastatic urothelial carcinoma: A case report

Saved in:

Bibliographic Details
Main Authors:	Yun-Chang Li, Sung-Lang Chen, Tung-Ying Ke, Tsu-Man Chiu
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-11-01
Series:	Dermatologica Sinica
Online Access:	https://journals.lww.com/10.4103/ds.DS-D-24-00062
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab
by: Benjamin Müller, et al.
Published: (2024-11-01)

Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
by: Daiki Ikarashi, et al.
Published: (2025-01-01)

Safety and Efficacy of Prophylactic Topical Steroid Administration for Enfortumab Vedotin–related Cutaneous Toxicity
by: Yuki Kita, et al.
Published: (2024-12-01)

Case report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin
by: Francine Fishbein, et al.
Published: (2024-11-01)

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
by: Toshiki Kijima, et al.
Published: (2025-01-01)

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
by: Siming Li, et al.
Published: (2024-11-01)

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma
by: Maura C. Gillis, BA, et al.
Published: (2025-02-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma
by: Suzy Van Sanden, et al.
Published: (2024-08-01)

Dramatic Response to Enfortumab Vedotin in Soft-tissue Metastases from Urothelial Carcinoma: A Case Report
by: Ming-Hsuan Wu, et al.
Published: (2024-12-01)

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
by: Jeanneth Elizabeth Jami Carrera, et al.
Published: (2024-11-01)

Steven’s Johnson Syndrome and Toxic Epidermal Necrolysis in Children
by: Hakan Turan, et al.
Published: (2008-01-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
by: Nobuaki Matsubara, et al.
Published: (2023-02-01)

Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
by: Grégoire Desimpel, et al.
Published: (2024-11-01)

Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum for the rheumatologist
by: Jyoti Ranjan Parida, et al.
Published: (2019-01-01)

The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China
by: Shang-Chen Yang, et al.
Published: (2018-01-01)

Severe cutaneous drug toxicity following disitamab vedotin treatment for metastatic gastric cancer: a case report
by: Zhao Luping, et al.
Published: (2025-01-01)

Corrigendum to “The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China”
by: Shang-Chen Yang, et al.
Published: (2018-01-01)

Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma
by: Osama Diab, et al.
Published: (2019-01-01)

Pembrolizumab-induced Stevens-Johnson syndrome-like reaction: An atypical clinical presentation
by: Arjun Mahajan, BS, MS, et al.
Published: (2024-12-01)

Carbamazepine Induced Stevens-Johnson Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the Literature
by: Yousef S. Abuzneid, et al.
Published: (2022-01-01)

Suçiçeği ile ilişkili Stevens-Johnson sendromu
by: Hasibe Artaç, et al.
Published: (2013-01-01)

Johnson, Steven (2020). El mapa fantasma
by: Ramsés Alejo Castañeda
Published: (2024-01-01)

Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo
by: Bayaki Saka, et al.
Published: (2019-01-01)

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess
by: Yuanbin Huang, et al.
Published: (2024-12-01)

Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome
by: Han Y. Yin, et al.
Published: (2020-01-01)

Is It Stevens–Johnson Syndrome or MIS-C with Mucocutaneous Involvement?
by: Abdollah Karimi, et al.
Published: (2021-01-01)

Clinico- Therapeutic Study of Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and Prognostic Significance of SCORTEN in Indian Patients
by: Neha Chetan Jangid, et al.
Published: (2024-01-01)

Lamotrigine-Valproic Acid Interaction Leading to Stevens–Johnson Syndrome
by: Marta Vázquez, et al.
Published: (2018-01-01)

A case of Stevens-Johnson syndrome treated with oral cyclosporine
by: Victoria Griffith, et al.
Published: (2023-12-01)

Flow Cytometric Analysis of Skin Blister Fluid Cells: A Promising Tool in the Differential Diagnosis of Acute Cutaneous Graft-versus-host Disease and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis
by: R. de Moraes Souza, et al.
Published: (2024-11-01)

Rifampicin-induced Stevens-Johnson Syndrome: A Rare Case Report
by: Bhaveshkumar Manilal Patel, et al.
Published: (2025-01-01)

Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream
by: Ilaria Salvi, et al.
Published: (2025-01-01)

A Singular Case Analysis: Lamotrigine-Associated Stevens–Johnson Syndrome
by: Albin Joshi, et al.
Published: (2024-01-01)

Erythema multiforme major/Stevens-Johnson syndrome: a diagnostic challenge
by: Rita Lages Pereira, et al.
Published: (2024-11-01)

Current surgical treatment options for ocular complications of Stevens-Johnson and Lyell's syndromes
by: V.F. Chernysh, et al.
Published: (2023-06-01)

Mycoplasma pneumoniae-Induced-Stevens Johnson Syndrome: Rare Occurrence in an Adult Patient
by: Samad Rasul, et al.
Published: (2012-01-01)

Stevens-Johnson Syndrome following Failure of Genetic Screening prior to Carbamazepine Prescription
by: Suraya Ahmad Nasir, et al.
Published: (2017-01-01)

Clinical and Epidemiological Features of Patients with Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iran: Different Points of Children from Adults
by: Bahareh Abtahi-Naeini, et al.
Published: (2022-01-01)

Epidemiological Characteristics and Prognostic Scoring in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome: Insights from a 17-Year Burn Center Experience
by: David Breidung, et al.
Published: (2025-01-01)